"Farnesyltranstransferase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the synthesis of geranylgeranyl diphosphate from trans, trans-farnesyl diphosphate and isopentenyl diphosphate.
| Descriptor ID |
D051231
|
| MeSH Number(s) |
D08.811.913.225.437
|
| Concept/Terms |
Farnesyltranstransferase- Farnesyltranstransferase
- Farnesyltransferase
- Geranylgeranyl Pyrophosphatase
- Pyrophosphatase, Geranylgeranyl
- GGDP Synthase
- Synthase, GGDP
- GGPP Synthase
- Synthase, GGPP
- Farnesyl Diphosphate-Geranylgeranyl Diphosphate Synthase
- Farnesyl Diphosphate Geranylgeranyl Diphosphate Synthase
- Geranylgeranyl-Diphosphate Synthase
- Geranylgeranyl Diphosphate Synthase
- Synthase, Geranylgeranyl-Diphosphate
|
Below are MeSH descriptors whose meaning is more general than "Farnesyltranstransferase".
Below are MeSH descriptors whose meaning is more specific than "Farnesyltranstransferase".
This graph shows the total number of publications written about "Farnesyltranstransferase" by people in this website by year, and whether "Farnesyltranstransferase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Farnesyltranstransferase" by people in Profiles.
-
Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors. Clin Cancer Res. 2019 10 01; 25(19):5984-5996.
-
Synthesis of Non-natural, Frame-Shifted Isoprenoid Diphosphate Analogues. Org Lett. 2016 12 02; 18(23):6038-6041.
-
A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease. PLoS Genet. 2012; 8(11):e1003042.
-
A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer. Int J Cancer. 2012 Aug 01; 131(3):537-47.
-
Developing consensus 3D-QSAR and pharmacophore models for several beta-secretase, farnesyl transferase and histone deacetylase inhibitors. J Mol Model. 2012 Feb; 18(2):675-92.
-
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005.
-
Farnesyltransferase inhibitors: where are we now? Expert Opin Investig Drugs. 2010 Dec; 19(12):1569-80.
-
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44.
-
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Feb; 56(2):226-33.
-
Current and future management options for myelodysplastic syndromes. Drugs. 2010 Jul 30; 70(11):1381-94.